Relay Therapeutics (RLAY) Stock Rating Upgrade Based on Trial Data

AI Summary

Relay Therapeutics (RLAY) received an upgrade in stock rating from Jones Trading following the release of new trial data. This upgrade reflects the company's ongoing commitment to advancing its drug development pipeline, which may enhance investor confidence. The specifics of the trial data were not disclosed in the report but are considered significant for future market performance. The upgrade could potentially influence trading volume and interest in RLAY stock among investors.